Trial Rationale

5.5 million patients  are affected by  NVAF worldwide

NVAF patients have  a 2-7x greater risk  of ischemic stroke

Current guidelines state that non-vitamin K antagonist oral anticoagulant (NOAC) therapy is the first line option for treatment of stroke risk reduction in non‑valvular atrial fibrillation (NVAF) patients. However, bleeding risk on these therapies compounds year over year, and are comparable across current pharmacotherapy options.

The bleeding risk associated with anticoagulants compounds year over year graph

*The HAS-BLED scoring system predicts a patients risk of stroke while on warfarin.
**Assumes constant risk despite increasing age, and bleeding risk is independent from bleeding risk in previous years.

The CHAMPION‑AF clinical trial seeks to demonstrate WATCHMAN FLX^TM is a first‑line stroke risk reduction therapy for most NVAF patients.

With this trial, Boston Scientific expands its LAAC leadership with unmatched clinical evidence intended to demonstrate WATCHMAN FLX is the optimal choice versus NOAC for lifelong stroke risk reduction.

Why LAA Closure?

With ~40% of oral anticoagulant (OAC) indicated patients left unprotected from stroke due to dissatisfaction and non-adherence with OACs, CHAMPION‑AF seeks to show WATCHMAN FLX as a first‑line option for stroke risk-reduction in most NVAF patients.⁷

Over 500,000 patients have already been successfully treated with WATCHMAN^TM LAAC technology.

Why CHAMPION-AF?

CHAMPION-AF is the largest left atrial appendage closure (LAAC) device trial that evaluates WATCHMAN FLX vs. NOAC as a first-line stroke risk reduction option for most NVAF patients.

Find a Trial Site

Boston Scientific has selected US sites to be CHAMPION-AF investigational centers. If you have a candidate in mind, view the active trial list provided by clinicaltrials.gov, and reach out to a study physician near you to discuss next steps for referral.

Site Locator

1. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the u.S. Adult population. The American journal of cardiology. 2013;112:1142-1147
2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. Acc/aha/esc 2006 guidelines for the management of patients with atrial fibrillation—executive summary: A report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol. 2006;48:854-906
3. Patel, M. NEJM 2011; 365(10): 883-891.
4. Granger, C. NEJM 2011; 365(11): 981-992.
5. Connolly, S. NEJM 2009; 361(12): 1139-1151.
6. Giugliano, R. NEJM 2013; 369(22): 2093-2104.
7. Marzec, et al. JACC 2017: 69(20): 2475-2484.

WATCHMAN FLX Device Brief Summary

Top